Coatue Management and Catalio Capital Management led a $165m Series C financing round in DNA Script.

Coatue Management, a global investment manager focused on public and private companies, and Catalio Capital Management, a venture capital investment company specialised in breakthrough biomedical technology companies, led a $165m Series C financing round in DNA Script, a pioneer in Enzymatic DNA Synthesis and DNA printing on demand. Additional investors include Fidelity Management and Research, Columbia Threadneedle Investments, Arrowmark Partners, Farallon Capital, Moore Strategic Ventures, Casdin Capital, LSP, Illumina Ventures, Bpifrance Large Venture Fund, Danaher Life Sciences, Agilent Technologies, M Ventures, Kurma Partners and Alexandria Venture Investments. “As we have seen with the success of COVID mRNA vaccines, we believe the next wave of life sciences will be an engineering and technology-based approach. We think DNA Script has changed the landscape with SYNTAX by replacing chemical processes with a plug-and-play technology that custom prints DNA on your lab bench,” Aaron Weiner, Coatue Management Managing Director and Head of Healthcare.